ArticleInflammation2025
March6 Protects Against Acute Kidney Injury by Suppressing Renal Tubular Epithelial Cell Ferroptosis Through the Destabilization of P53 and ACSL4 Proteins.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Lipocalin 2: a double-edged sword in cellular ferroptosis.Cell biology and toxicology · 2026Review
- The role of ferroptosis in acute kidney injury: the preemptive mode of cell death and the bridging effect.Renal failure · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) progression involves significant contributions from renal tubular epithelial cell ferroptosis. Membrane associated RING finger protein 6 (March6) is implicated in modulating ferroptosis by regulating the stability of related proteins, yet its specific role in tubular epithelial cell ferroptosis and AKI progression remains unknown. This work seeks to clarify the regulatory role of March6 in the ferroptosis of tubular epithelial cells and its involvement in AKI using ischemia-reperfusion injury (IRI)-induced animal models and hypoxia/reoxygenation (H/R)-induced cellular models. Our results demonstrated a significant reduction in March6 expression in renal tissues from IRI mice and H/R cells, accompanied by elevated PTGS2 and reduced GPX4 levels, two ferroptosis marker proteins. Overexpression of March6 in HK-2 cells significantly counteracted Erastin-induced ferroptosis, whereas silencing March6 increased susceptibility. In H/R models, March6 overexpression enhanced cell viability and lowered cell death, reversing ferroptosis-related changes, whereas silencing March6 exhibited the opposite effects. Tubular-specific overexpression of March6 in mice with IRI-induced AKI notably mitigated kidney damage and suppressed ferroptotic changes. Mechanistically, March6 inhibited ferroptosis by accelerating the degradation of key pro-ferroptotic proteins ACSL4 and p53. Co-immunoprecipitation (Co-IP) experiments validated the direct interaction between March6 and p53 or ACSL4. Overexpressing ACSL4 or p53 in March6-overexpressing HK-2 cells markedly reversed March6's protective effects against H/R-induced damage and ferroptosis. Collectively, March6 mitigates ferroptosis in renal tubular epithelial cells by promoting the degradation of ACSL4 and p53, thereby alleviating AKI progression. This study not only uncovers a novel regulatory mechanism of tubular epithelial cell ferroptosis in AKI but also provides a potential therapeutic target for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.